 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
2 News |  |
| «12...6789101112131415161718» |
- ||| Tecvayli (teclistamab) / Genmab, J&J
With emerging Congress abstract data from 2022 EHA & ASCO Teclistamab combos are performing better and deserves to be preferred instead of mono (Twitter) - Jul 23, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Clinical, European regulatory: Positive CHMP Opinion for Bispecific Antibody teclistamab for the Treatment of Patients with Relapsed and Refractory Myeloma @TheIACH @COMyCongress @JanssenEMEA - Great news for a hard to treat group of patients https://t.co/VS6hau3vVX (Twitter) - Jul 22, 2022
- Tecvayli (teclistamab) / Genmab, J&J
Comparative efficacy of teclistamab versus real-world physician’s choice of therapy in the prospective LocoMMotion study in patients with triple-class exposed relapsed/refractory multiple myeloma (Petree Hall C) - Jul 21, 2022 - Abstract #IMW2022IMW_178;
P=N/A, P2
Teclistamab showed significantly improved efficacy over RW physician’s choice of therapy for all outcomes, highlighting its clinical benefit as a highly effective tx option for pts with TCE RRMM who have been exposed to ≥3 LOT.
- |||||| Tecvayli (teclistamab) / Genmab, J&J
New trial: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients (clinicaltrials.gov) - Jul 19, 2022
P=N/A, N=0, Available, Sponsor: Janssen Research & Development, LLC
- || parsaclisib (INCB50465) / Incyte, teclistamab (JNJ-64007957) / Genmab, J&J
EU Decision Time For Teclistamab & Seven Other Drugs; Incyte Withdraws Parsaclisib Filing https://t.co/An8qoHLvWP #PinkSheet (Twitter) - Jul 18, 2022
- || Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
Enrollment change, Combination therapy, Checkpoint inhibition: TRIMM-3: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 15, 2022
P1b, N=152, Recruiting, Sponsor: Janssen Research & Development, LLC
Teclistamab showed significantly improved efficacy over RW physician’s choice of therapy for all outcomes, highlighting its clinical benefit as a highly effective tx option for pts with TCE RRMM who have been exposed to ≥3 LOT. N=76 --> 152
- || Tecvayli (teclistamab-cqyv) / Genmab, J&J
Enrollment change, IO biomarker: MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 15, 2022
P1, N=282, Recruiting, Sponsor: Janssen Research & Development, LLC
N=76 --> 152 N=204 --> 282
- |||| teclistamab (JNJ-64007957) / Genmab, J&J
Clinical, HEOR, Patient reported outcomes: Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1 @AjayNookaMD https://t.co/tqcrJQds5m via @onclive (Twitter) - Jul 14, 2022
- || teclistamab (JNJ-64007957) / Genmab, J&J
classic chemo bringing and wait for teclistamab approval (Twitter) - Jul 3, 2022
- |||||| teclistamab (JNJ-64007957) / Genmab, J&J
Clinical: Teclistimab: Advantages: Has efficacy as single agent Off the shelf Many community clinics can use it low % III/IV CRS/ICANS Disadvantages High rate of infection Weekly treatment compared to one treatment CAR-T Unknown which treatment is the best in triple-Class RRMM (Twitter) - Jun 26, 2022
- |||| lenalidomide / Generic mfg., teclistamab (JNJ-64007957) / Genmab, J&J, talquetamab (JNJ-64407564) / J&J
CAR T-Cell Therapy: #myeloma from Dr Vij from @SitemanCenter #ASCO22 📣 Ext duration lenalidomide SOC postautologous transplant 📣 Teclistamab expected as 1st bispecific Ab to BCMA approved 📣Talquetamab & covestamab active bispecifics to GPRCSD and FCRHS 📣CART cells to BCMA avail but ltd avail (Twitter) - Jun 25, 2022
- ||| teclistamab (JNJ-64007957) / Genmab, J&J
@szusmani I'm looking at Teclistimab data. With infection rate of 76.4% w/ 44.8% gr 3/4 are you looking at prophylactic antibiotics with tx? (Twitter) - Jun 23, 2022
- |||| teclistamab (JNJ-64007957) / Genmab, J&J, talquetamab (JNJ-64407564) / J&J
Clinical: BCMA BsAb (teclistamab) vs GPRC5D BsAb (talquetamab) - perhaps more infections with BCMA, but more skin/nail/mucositis w GPRC5D (can be Rx-limiting). Promising efficacy of teclistamab among pts w prev BCMA exposure (52% ORR) @Mohty_EBMT (Twitter) - Jun 21, 2022
- | Tecvayli (teclistamab) / Genmab, J&J, Talvey (talquetamab) / J&J
Trial completion date: RedirecTT-1: A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 21, 2022
P1b, N=56, Recruiting, Sponsor: Janssen Research & Development, LLC
N=204 --> 282 Trial completion date: Nov 2023 --> May 2024
- ||| Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
Enrollment open, Enrollment change, Combination therapy, Checkpoint inhibition: TRIMM-3: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 20, 2022
P1b, N=76, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Nov 2023 --> May 2024 Not yet recruiting --> Recruiting | N=152 --> 76
- ||| teclistamab (JNJ-64007957) / Genmab, J&J, iberdomide (CC-220) / BMS
Thanks for sharing and that sounds very reasonable. 2 questions: 1) are you at all concerned about teclistamab chronic infections from prolonged dosing period? 2) where does iberdomide get placed in the complicated imid treatment sequencing? (Twitter) - Jun 19, 2022
- || teclistamab (JNJ-64007957) / Genmab, J&J
Teclistamab + Dara better than other salvage therapies , what do you think ? https://t.co/kJLk8yDuVC (Twitter) - Jun 19, 2022
- |||| FDA event: If Teclistamab/Iberdomide got an FDA approval this year & based on our data analysis these drugs will be out of the game: Selinexor Ixazomib Belantamab Isatuximab/Elotuzomab Drugs that will stay: CAR-T Pom/Len Darzlex Velcade/Carfilzomib Mel/Cytoxan Venetocloax t(11;14) #mmsm (Twitter) - Jun 19, 2022
- ||| teclistamab (JNJ-64007957) / Genmab, J&J
Next-generation sequencing: In BCMA exposed/refractory MM (n=40), Teclistamab SC shows a response rate 52.5%, MRD- 17.5% at 10-5 via NGS, CRS ~70% (grade 1/2), 15/21 responders maintaining response at a median follow-up 11.8 months https://t.co/59IKhBo2Pu #CARTSM #ASCO22 #ASCO22_SZU #MedIQ22ASCO #EHA2022 (Twitter) - Jun 11, 2022
- ||| teclistamab (JNJ-64007957) / Genmab, J&J, Darzalex Faspro (daratumumab/hyaluronidase) / J&J
Next-generation sequencing: Teclistamab SC combined with Daratumumab SC, weekly/q2 weekly dosing schedules, shows a response rate 78%, MRD- 27% at 10-5 via NGS, CRS ~61% (grade 1/2), median follow-up of 7.2 months. https://t.co/tFV5YyeAWH #CARTSM #ASCO22 #ASCO22_SZU #MedIQ22ASCO #EHA2022 (Twitter) - Jun 11, 2022
- |||| teclistamab (JNJ-64007957) / Genmab, J&J
Next-generation sequencing: Teclistamab SC showed a response rate of 63%, MRD- 27% at 10-5 via NGS, CRS ~70% (grade 1/2), ICANS 3 % (grade 1/2),median PFS 11.3 months, median DoR 18.4 months, median follow-up 14 months. https://t.co/X1flVqOCke #CARTSM #ASCO22 #ASCO22_SZU #MedIQ22ASCO #EHA2022 (Twitter) - Jun 11, 2022
- |||| elranatamab (PF-06863135) / Pfizer, teclistamab (JNJ-64007957) / Genmab, J&J, linvoseltamab (REGN5458) / Regeneron
P1 data: Bispecific antibodies are showing unprecedented single agent activity in relapsed/refractory MM. There are several phase I trials in this setting, let’s see at the data shared at #ASCO22 and #EHA2022 with Teclistamab , Elranatamab and REGN5458 targeting BCMA and… (Twitter) - Jun 11, 2022
- ||| teclistamab (JNJ-64007957) / Genmab, J&J
MajesTEC- Teclistamab- Touzeau #MMSM #EHA2022 (Twitter) - Jun 11, 2022
- ||| teclistamab (JNJ-64007957) / Genmab, J&J
MajecTEC - Teclistamab- Touzeau #EHA2022 #MMSM (Twitter) - Jun 11, 2022
- |||| teclistamab (JNJ-64007957) / Genmab, J&J
Good responses with Teclistamab after a prior BCMA therapy. Early data to support BCMA re-treatment. #EHA2022 #mmsm (Twitter) - Jun 11, 2022
- |||| teclistamab (JNJ-64007957) / Genmab, J&J
Clinical: More and more possibilities for myeloma patients! Teclistamab in Relapsed or Refractory Multiple Myeloma | NEJM https://t.co/FzLiJDzNzM (Twitter) - Jun 11, 2022
- ||| teclistamab (JNJ-64007957) / Genmab, J&J
Adding DARA to Teclistamab #EHA2022 #mmsm (Twitter) - Jun 10, 2022
- || teclistamab (JNJ-64007957) / Genmab, J&J
Teclistamab vs others therapies in RRMM #EHA2022 (Twitter) - Jun 10, 2022
- || teclistamab (JNJ-64007957) / Genmab, J&J
Teclistamab in RRMM #EHA2022 (Twitter) - Jun 10, 2022
- ||||| teclistamab (JNJ-64007957) / Genmab, J&J
Video: A short clip from my full video of Teclistimab The RR is good The Infection rate is mind-boggling How can an uncontrolled study adjudicate off target/ non cancer harm and on target/ on cancer benefit? #ASCO22 #ASCO2022 Watch the full video here: https://t.co/DLvxuzXkW9 (Twitter) - Jun 10, 2022
- ||| teclistamab (JNJ-64007957) / Genmab, J&J
Teclistimab Lots of responses Lots of infection/ Covid How should we think about the NEJM paper #ASCO22 My take @Plenary_Session https://t.co/JQ05ESq76a (Twitter) - Jun 9, 2022
- |||| teclistamab (JNJ-64007957) / Genmab, J&J
We are 1 hour away from Teclistimab in Myeloma, an analysis Coming to.... https://t.co/s8TLq5pt0q (Twitter) - Jun 9, 2022
- || teclistamab (JNJ-64007957) / Genmab, J&J
There isn’t much data but responses are seen, perhaps a little lower but too early to call. Likewise with ADCs prior to Teclistamab. Seems different to the CD38 Mab story. (Twitter) - Jun 9, 2022
- ||| teclistamab (JNJ-64007957) / Genmab, J&J
Teclistamab showed 63% ORR and 27% MRD neg in relapsed/refectory myeloma, median duration of response 18.4 months. Congrats Moreau, @szusmani et al @NEJM @MSKCancerCenter #mmsm https://t.co/L94KI6LqrA (Twitter) - Jun 9, 2022
- ||| teclistamab (JNJ-64007957) / Genmab, J&J, Jemperli (dostarlimab) / GSK
Although no one wants to admit it; the most discussed #ASCO22 #ASCO2022 presentations are these 5 Ranging from Dostarlimab (praise) to Shine (condemnation) I stand by all 5, & I haven't seen other deep analyses Teclistimab is coming next.... https://t.co/s8TLq5pt0q (Twitter) - Jun 8, 2022
- |||| teclistamab (JNJ-64007957) / Genmab, J&J
Minimal residual disease: Teclistamab results in relapsed refractory myeloma published in @NEJM. Response rate of 63% and MRD negative rate of 27% are very impressive. Median PFS was 11 months with this bispecific antibody. Congrats @szusmani and co authors. https://t.co/UUOw4UJeqM (Twitter) - Jun 8, 2022
- |||| teclistamab (JNJ-64007957) / Genmab, J&J
CART 1 infusion and that’s it. ORR in tripleCR 97%, CR 82%. Problem access, manufacturing time. Teclistamab If approved immediately available (no manufacturing). More discrete response but effective. Long lasting treatment. Manageable side CRS/ICANS/Infections, both. (Twitter) - Jun 7, 2022
- || teclistamab (JNJ-64007957) / Genmab, J&J
Not that my opinion matters, but teclistamabs impact in MM is only just beginning. Really looking to IMID-free and steroid sparing regimens in early line MM. You all talk about QoL a lot, but both IMiDs and chronic steroids aren't moving this metric in the right direction. (Twitter) - Jun 7, 2022
- || teclistamab (JNJ-64007957) / Genmab, J&J
I have been teasing him about his pro teclistamab stance all week ! #gamechanger #asco22 (Twitter) - Jun 6, 2022
- || teclistamab (JNJ-64007957) / Genmab, J&J, Blenrep (belantamab mafodotin) / GSK
Surprised to see that Idecel after Blenrep is not working very well. Any thoughts how good Idecel or Ciltacel might work after Teclistimab? (Twitter) - Jun 6, 2022
- || teclistamab (JNJ-64007957) / Genmab, J&J
The ease of delivery/accessibility of Teclistimab is attractive, but if accessible, I’d probably lean cilta at this point. Also might be a good opportunity to build a decision model to help factor in all the available data and potential complications. (Twitter) - Jun 6, 2022
- || teclistamab (JNJ-64007957) / Genmab, J&J, Carvykti (ciltacabtagene autoleucel) / J&J
IMO cilta-cel over teclistamab (Twitter) - Jun 6, 2022
- |||| teclistamab (JNJ-64007957) / Genmab, J&J
Clinical: Winship #multiplemyeloma expert @AjayNookaMD is co-author of a study published in @NEJM showing promising efficacy for teclistamab in patients with relapsed or refractory multiple myeloma. Dr. Nooka is presenting the study results today at #ASCO22. ➡️ https://t.co/TTluuwyu8b (Twitter) - Jun 5, 2022
- ||| teclistamab (JNJ-64007957) / Genmab, J&J
If Teclistamab got approved! What treatment will u choose for triple class RRMM after 4 LOT #mmsm #myeloma #MedTwitter (Twitter) - Jun 5, 2022
- ||||| teclistamab (JNJ-64007957) / Genmab, J&J
Clinical: MajesTEC-1: Teclistamab in 165 pts with RRMM, 78%, 30%, 25% triple, Penta Class RRMM and HR myeloma respectively. RR 63%, DOR 18 months, PFS 11 months, OS 18 months #mmsm #medEd #MedTwitter (Twitter) - Jun 5, 2022
- ||||| teclistamab (JNJ-64007957) / Genmab, J&J
Minimal residual disease: MajesTEC-1 results presented by @AjayNookaMD @szusmani Teclistamab ORR 63%; MRD negativity rate 27% mPFS 11.3 months Just published in NEJM #mmsm #ASCO2022 @MSKCancerCenter https://t.co/WpmZvf6T7o (Twitter) - Jun 5, 2022
- ||||| teclistamab (JNJ-64007957) / Genmab, J&J
Clinical: Teclistamab in Relapsed or Refractory MM #mmsm #ASCO22 @NEJM ➡️Excellent results in heavily pre-treated pts👇 ➡️Hope this new response rates will make us move away from "less effective" agents and provide pts with better options. congrats all authors @szusmani impressive work (Twitter) - Jun 5, 2022
- |||| teclistamab (JNJ-64007957) / Genmab, J&J
Clinical: I look forward to this approval in multiple myeloma. Especially since it has been near impossible to get my patients CART off trial. Teclistamab in Relapsed or Refractory Multiple Myeloma | NEJM https://t.co/P5HAOQRuAi (Twitter) - Jun 5, 2022
- ||| teclistamab (JNJ-64007957) / Genmab, J&J
Teclistamab in Relapsed or Refractory Multiple Myeloma | NEJM Exciting step forward in terms of immune therapy for myeloma https://t.co/kDVB9QwRYp (Twitter) - Jun 5, 2022
- |||| teclistamab (JNJ-64007957) / Genmab, J&J
Clinical, Adverse events: In terms of safety, 19 patients died from adverse events, including 12 from COVID-19. 5 were considered to be related to teclistamab: 1 due to PML, 2 who had contracted COVID-19, 1 who had hepatic failure, and 1 who had strep pneumonia. (Twitter) - Jun 5, 2022